Differential effect of amyloid beta peptides on mitochondrial axonal trafficking depends on their state of aggregation and binding to the plasma membrane

Liang Zhang, Sergey Trushin, Trace A. Christensen, Utkarsh Tripathi, Courtney Hong, Rachel E. Geroux, Kyle G. Howell, Joseph F. Poduslo, Eugenia D Trushina

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Inhibition of mitochondrial axonal trafficking by amyloid beta (Aβ) peptides has been implicated in early pathophysiology of Alzheimer's Disease (AD). Yet, it remains unclear whether the loss of motility inevitably induces the loss of mitochondrial function, and whether restoration of axonal trafficking represents a valid therapeutic target. Moreover, while some investigations identify Aβ oligomers as the culprit of trafficking inhibition, others propose that fibrils play the detrimental role. We have examined the effect of a panel of Aβ peptides with different mutations found in familial AD on mitochondrial motility in primary cortical mouse neurons. Peptides with higher propensity to aggregate inhibit mitochondrial trafficking to a greater extent with fibrils inducing the strongest inhibition. Binding of Aβ peptides to the plasma membrane was sufficient to induce trafficking inhibition where peptides with reduced plasma membrane binding and internalization had lesser effect on mitochondrial motility. We also found that Aβ peptide with Icelandic mutation A673T affects axonal trafficking of mitochondria but has very low rates of plasma membrane binding and internalization in neurons, which could explain its relatively low toxicity. Inhibition of mitochondrial dynamics caused by Aβ peptides or fibrils did not instantly affect mitochondrial bioenergetic and function. Our results support a mechanism where inhibition of axonal trafficking is initiated at the plasma membrane by soluble low molecular weight Aβ species and is exacerbated by fibrils. Since trafficking inhibition does not coincide with the loss of mitochondrial function, restoration of axonal transport could be beneficial at early stages of AD progression. However, strategies designed to block Aβ aggregation or fibril formation alone without ensuring the efficient clearance of soluble Aβ may not be sufficient to alleviate the trafficking phenotype.

Original languageEnglish (US)
Pages (from-to)1-16
Number of pages16
JournalNeurobiology of Disease
Volume114
DOIs
StatePublished - Jun 1 2018

Fingerprint

Amyloid beta-Peptides
Cell Membrane
Peptides
Alzheimer Disease
Mitochondrial Dynamics
Neurons
Mutation
Axonal Transport
Inhibition (Psychology)
Energy Metabolism
Disease Progression
Mitochondria
Molecular Weight
Phenotype

Keywords

  • Aggregation
  • Alzheimer's disease
  • Amyloid beta peptides
  • Atomic force microscopy
  • Axonal transport
  • Bioenergetics
  • Dynamic light scattering
  • Electron microscopy
  • Endocytosis
  • Fibrils
  • Mitochondria
  • Mitochondrial function
  • Mouse models of AD
  • Oligomers
  • Plasma membrane binding
  • Primary neurons
  • Seahorse extracellular flux analyzer

ASJC Scopus subject areas

  • Neurology

Cite this

Differential effect of amyloid beta peptides on mitochondrial axonal trafficking depends on their state of aggregation and binding to the plasma membrane. / Zhang, Liang; Trushin, Sergey; Christensen, Trace A.; Tripathi, Utkarsh; Hong, Courtney; Geroux, Rachel E.; Howell, Kyle G.; Poduslo, Joseph F.; Trushina, Eugenia D.

In: Neurobiology of Disease, Vol. 114, 01.06.2018, p. 1-16.

Research output: Contribution to journalArticle

Zhang, Liang ; Trushin, Sergey ; Christensen, Trace A. ; Tripathi, Utkarsh ; Hong, Courtney ; Geroux, Rachel E. ; Howell, Kyle G. ; Poduslo, Joseph F. ; Trushina, Eugenia D. / Differential effect of amyloid beta peptides on mitochondrial axonal trafficking depends on their state of aggregation and binding to the plasma membrane. In: Neurobiology of Disease. 2018 ; Vol. 114. pp. 1-16.
@article{fccb2008de304771b154afe620ac30f5,
title = "Differential effect of amyloid beta peptides on mitochondrial axonal trafficking depends on their state of aggregation and binding to the plasma membrane",
abstract = "Inhibition of mitochondrial axonal trafficking by amyloid beta (Aβ) peptides has been implicated in early pathophysiology of Alzheimer's Disease (AD). Yet, it remains unclear whether the loss of motility inevitably induces the loss of mitochondrial function, and whether restoration of axonal trafficking represents a valid therapeutic target. Moreover, while some investigations identify Aβ oligomers as the culprit of trafficking inhibition, others propose that fibrils play the detrimental role. We have examined the effect of a panel of Aβ peptides with different mutations found in familial AD on mitochondrial motility in primary cortical mouse neurons. Peptides with higher propensity to aggregate inhibit mitochondrial trafficking to a greater extent with fibrils inducing the strongest inhibition. Binding of Aβ peptides to the plasma membrane was sufficient to induce trafficking inhibition where peptides with reduced plasma membrane binding and internalization had lesser effect on mitochondrial motility. We also found that Aβ peptide with Icelandic mutation A673T affects axonal trafficking of mitochondria but has very low rates of plasma membrane binding and internalization in neurons, which could explain its relatively low toxicity. Inhibition of mitochondrial dynamics caused by Aβ peptides or fibrils did not instantly affect mitochondrial bioenergetic and function. Our results support a mechanism where inhibition of axonal trafficking is initiated at the plasma membrane by soluble low molecular weight Aβ species and is exacerbated by fibrils. Since trafficking inhibition does not coincide with the loss of mitochondrial function, restoration of axonal transport could be beneficial at early stages of AD progression. However, strategies designed to block Aβ aggregation or fibril formation alone without ensuring the efficient clearance of soluble Aβ may not be sufficient to alleviate the trafficking phenotype.",
keywords = "Aggregation, Alzheimer's disease, Amyloid beta peptides, Atomic force microscopy, Axonal transport, Bioenergetics, Dynamic light scattering, Electron microscopy, Endocytosis, Fibrils, Mitochondria, Mitochondrial function, Mouse models of AD, Oligomers, Plasma membrane binding, Primary neurons, Seahorse extracellular flux analyzer",
author = "Liang Zhang and Sergey Trushin and Christensen, {Trace A.} and Utkarsh Tripathi and Courtney Hong and Geroux, {Rachel E.} and Howell, {Kyle G.} and Poduslo, {Joseph F.} and Trushina, {Eugenia D}",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.nbd.2018.02.003",
language = "English (US)",
volume = "114",
pages = "1--16",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Differential effect of amyloid beta peptides on mitochondrial axonal trafficking depends on their state of aggregation and binding to the plasma membrane

AU - Zhang, Liang

AU - Trushin, Sergey

AU - Christensen, Trace A.

AU - Tripathi, Utkarsh

AU - Hong, Courtney

AU - Geroux, Rachel E.

AU - Howell, Kyle G.

AU - Poduslo, Joseph F.

AU - Trushina, Eugenia D

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Inhibition of mitochondrial axonal trafficking by amyloid beta (Aβ) peptides has been implicated in early pathophysiology of Alzheimer's Disease (AD). Yet, it remains unclear whether the loss of motility inevitably induces the loss of mitochondrial function, and whether restoration of axonal trafficking represents a valid therapeutic target. Moreover, while some investigations identify Aβ oligomers as the culprit of trafficking inhibition, others propose that fibrils play the detrimental role. We have examined the effect of a panel of Aβ peptides with different mutations found in familial AD on mitochondrial motility in primary cortical mouse neurons. Peptides with higher propensity to aggregate inhibit mitochondrial trafficking to a greater extent with fibrils inducing the strongest inhibition. Binding of Aβ peptides to the plasma membrane was sufficient to induce trafficking inhibition where peptides with reduced plasma membrane binding and internalization had lesser effect on mitochondrial motility. We also found that Aβ peptide with Icelandic mutation A673T affects axonal trafficking of mitochondria but has very low rates of plasma membrane binding and internalization in neurons, which could explain its relatively low toxicity. Inhibition of mitochondrial dynamics caused by Aβ peptides or fibrils did not instantly affect mitochondrial bioenergetic and function. Our results support a mechanism where inhibition of axonal trafficking is initiated at the plasma membrane by soluble low molecular weight Aβ species and is exacerbated by fibrils. Since trafficking inhibition does not coincide with the loss of mitochondrial function, restoration of axonal transport could be beneficial at early stages of AD progression. However, strategies designed to block Aβ aggregation or fibril formation alone without ensuring the efficient clearance of soluble Aβ may not be sufficient to alleviate the trafficking phenotype.

AB - Inhibition of mitochondrial axonal trafficking by amyloid beta (Aβ) peptides has been implicated in early pathophysiology of Alzheimer's Disease (AD). Yet, it remains unclear whether the loss of motility inevitably induces the loss of mitochondrial function, and whether restoration of axonal trafficking represents a valid therapeutic target. Moreover, while some investigations identify Aβ oligomers as the culprit of trafficking inhibition, others propose that fibrils play the detrimental role. We have examined the effect of a panel of Aβ peptides with different mutations found in familial AD on mitochondrial motility in primary cortical mouse neurons. Peptides with higher propensity to aggregate inhibit mitochondrial trafficking to a greater extent with fibrils inducing the strongest inhibition. Binding of Aβ peptides to the plasma membrane was sufficient to induce trafficking inhibition where peptides with reduced plasma membrane binding and internalization had lesser effect on mitochondrial motility. We also found that Aβ peptide with Icelandic mutation A673T affects axonal trafficking of mitochondria but has very low rates of plasma membrane binding and internalization in neurons, which could explain its relatively low toxicity. Inhibition of mitochondrial dynamics caused by Aβ peptides or fibrils did not instantly affect mitochondrial bioenergetic and function. Our results support a mechanism where inhibition of axonal trafficking is initiated at the plasma membrane by soluble low molecular weight Aβ species and is exacerbated by fibrils. Since trafficking inhibition does not coincide with the loss of mitochondrial function, restoration of axonal transport could be beneficial at early stages of AD progression. However, strategies designed to block Aβ aggregation or fibril formation alone without ensuring the efficient clearance of soluble Aβ may not be sufficient to alleviate the trafficking phenotype.

KW - Aggregation

KW - Alzheimer's disease

KW - Amyloid beta peptides

KW - Atomic force microscopy

KW - Axonal transport

KW - Bioenergetics

KW - Dynamic light scattering

KW - Electron microscopy

KW - Endocytosis

KW - Fibrils

KW - Mitochondria

KW - Mitochondrial function

KW - Mouse models of AD

KW - Oligomers

KW - Plasma membrane binding

KW - Primary neurons

KW - Seahorse extracellular flux analyzer

UR - http://www.scopus.com/inward/record.url?scp=85042485360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042485360&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2018.02.003

DO - 10.1016/j.nbd.2018.02.003

M3 - Article

C2 - 29477640

AN - SCOPUS:85042485360

VL - 114

SP - 1

EP - 16

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

ER -